Matthew Rosencranz

Matthew Rosencranz is an associate in Goodwin’s Business Law department and a member of its nationally recognized Technology and Life Sciences groups. 

He advises companies, and venture capital and growth equity investors on a wide array of corporate matters, including seed, venture and growth equity financings, public securities offerings, mergers and acquisitions, and other strategic and cross-border transactions. 

Matthew also advises clients on a range of ongoing SEC compliance matters and capital markets transactions, including initial public offerings and other equity offerings, tender offers, and PIPE transactions, and high-yield, investment-grade and convertible debt offerings. He joined Goodwin in 2019.

Matthew’s representative clients, among others, include advising:

Technology:

• A24 Films
• Alloy Enterprises (sold to Johnson Controls)
• Allego
• Brightcove (Formerly NASDAQ: BCOV, sold to Bending Spoons)
• Circle Internet Group (NYSE: CRCL)
• Dynatrace (NYSE: DT)
• Juna.ai
• Klaviyo (NYSE: KVYO)
• Mobeewave (sold to Apple)
• Starburst Data
• Vatn Systems
• Vicor (NASDAQ: VICR)

Life Sciences:

• Boston Scientific (NYSE: BSX)
• Kymera Therapeutics Inc. (NASDAQ: KYMR)
• Moderna (NASDAQ: MRNA)
• MorphyoSys (Formerly NASDAQ: MOR, sold to Novartis)
• Obsidian Therapeutics (NASDAQ: OBX)
• SC Therapeutics
• TruDataRx
• Virex Health (sold to Sorrento Therapeutics)

Venture Capital and Growth Equity:

• Accel
• Alder Vale
• Curie.Bio 
• DST Global 
• Earlybird Ventures 
• F-Prime 
• Marshall Wace
• Mendon Venture Partners 
• Milky Way Investments 
• New Enterprise Associates
• Newlands
• RA Capital Management
• Visionaries Club
• Wellington Management Company 
• Will Ventures

While in law school, Matthew served as a judicial intern at the U.S. District Court for the District of Massachusetts and at the Massachusetts Supreme Judicial Court. He also served as an editor of the Suffolk University Law Review.